Project Details


This Research Collaboration Agreement sets out the terms to conduct the trials endTB (the O2 trial to test new regimens to treat multidrug resistant tuberculosis) and endTB-Q (the O5 trial to test new regimes to treat MDR-TB resistant to fluroquinilones) sponsored by MSF. Main responsibility of ITM is to serve as reference laboratory for the trials and conduct mycobacterial analyses of human biological samples according to the protocol.
Effective start/end date1/06/1631/08/23


  • MSF France: €1,274,947.89


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.